GC Pharma Corp., formerly Green Cross Corp., of Yongin, South Korea, plans to start enrollment in a phase II/III trial testing GC-1102 (hepabig-gene) to prevent the recurrence of hepatitis B virus infection following liver transplantation in early 2018.